In an exclusive and wide-ranging interview, Takeda APAC SVP Thomas Willemsen outlines his strategy for bringing the company’s specialty pharma portfolio to the diverse group of countries that make up the APAC region, the potential significance of Takeda’s upcoming dengue vaccine, and what Asia’s contribution to global healthcare and life sciences can be.
The big picture trends of ageing populations and rising affluence, which lead to greater demand for specialty care products, are universal and, if anything, are moving faster in emerging markets than in the developed world
